Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

NextMeds vs NovoCare Pharmacy

NextMeds
Graded #191

Higher grade

vs+11.099999999999994
NovoCare Pharmacy
Graded #442

Lower grade

The verdict

NextMeds takes it — 66.3/100 to 55.2/100.

NextMeds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NextMeds is a cash-pay telehealth platform offering compounded semaglutide and compounded tirzepatide on a flat monthly membership — one price bundling the medication (if prescribed), telehealth visits, a…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueNextMeds +32
56
24
Dose & formulationNovoCare Pharmacy +2
64
66
Clinical oversightNextMeds +3
77
74
Labs & monitoringNextMeds +10
61
51
FulfillmentNextMeds +8
84
76
Contract termsNextMeds +6
61
55
NextMeds · left barNovoCare Pharmacy · right bar

The numbers

MetricNextMedsNovoCare Pharmacy
WeighScore66.3/10055.2/100
GradeCC
Scorecard rank#191#442
Semaglutide$129/mo (plus a separate fee, compounded)$349/mo (2.4 mg dose, brand-name)
Tirzepatide$179/mo (plus a separate fee, compounded)Not disclosed
CoverageAll 50 statesAll 50 states
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyYes
NextMeds

Graded #191 · C

Strengths

  • Flat monthly membership bundles the medication, telehealth visits, a 1:1 care coach and a licensed registered dietitian — one price, no hidden fees
  • Same price every dose, no auto-renewal, cancel anytime; free shipping and no insurance needed (FSA eligible)
  • Names a compounding pharmacy partner (Foothills Pharmacy) and states it services all 50 states
  • Free, no-obligation online assessment before you pay anything

Where it loses points

  • Shows a LegitScript 'approval' but links only a generic directory search, not a verifiable seal — we couldn't independently confirm it
  • Promo-driven pricing with a countdown timer and 'price increases' urgency; the standing membership is $129 (sema) / $179 (tirz)
  • A technology platform that coordinates care, not the medical provider; individual clinicians and a medical director aren't named on the site
  • Compounded semaglutide and tirzepatide only — no brand-name (Wegovy/Zepbound) options
  • Compounded GLP-1s are not FDA-reviewed or approved — a different evidence and regulatory tier than brand-name
NovoCare Pharmacy

Graded #442 · C

Strengths

  • First-party Novo Nordisk pharmacy — the most authoritative branded Wegovy channel
  • $199/mo intro pricing on Wegovy 0.25/0.5 mg starter doses (through 6/30/2026), the lowest brand self-pay price
  • $349/mo standard self-pay is well below the ~$1,300/mo retail list price
  • Ships to all 50 states with no telehealth-platform middleman fees
  • Cold-chain logistics handled directly by Novo Nordisk

Where it loses points

  • Wegovy only — no Ozempic, no tirzepatide, no compounded GLP-1
  • Requires an existing Wegovy prescription — no prescribing clinicians or telehealth intake
  • No clinical support included — your own prescriber handles titration and side effects
  • Manufacturer-set pricing can change at any time
  • $199 pen intro covers only the first 2 fills for new patients (through 6/30/2026); maintenance doses are $349/mo ($399 HD)

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard